BKV nephropathy (BKV) is one of the most frequent complications of kidney transplantation. In the absence of specific anti-BKV treatment, pre-emptive reduction of immunosuppression is the main strategy that has proven effective in reducing the risk of BKVN. However, it exposes a transplant rejection risk estimated between 4 and 14% according to studies. Despite the pre-emptive reduction of immunosuppression, a significant number of patients continue to progress towards BKVN suggesting that pre-emptive strategy is late. It's therefore urgent to develop new prognostic markers to identify earlier and more effectively patients with a higher risk of developing BKVN.
Study Type
OBSERVATIONAL
Enrollment
170
Service de Virologie - Hôpital Civil
Strasbourg, France, France
Quantification of anti-BKV
Time frame: up to 12 months post-transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.